KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
默克(US:MRK) Businesswire·2025-10-18 22:30核心观点 - KEYTRUDA联合Padcev作为肌层浸润性膀胱癌患者术前术后治疗方案 相比单独手术可将无事件生存事件风险降低60% 并将死亡风险降低50% [1] 临床试验结果 - 在LEAP-015临床试验中 KEYTRUDA联合Padcev方案对比当前标准护理单独手术显示出显著优势 [1] - 该联合疗法针对不适合接受以顺铂为基础化疗的肌层浸润性膀胱癌患者 [1] 治疗方案 - 联合治疗方案应用于根治性膀胱切除术之前和之后 [1]